Stratified analysis | Trials | n | Vasopressin | P value | Heterogeneity | Terlipressin | P value | Heterogeneity |
---|---|---|---|---|---|---|---|---|
Mortality | ||||||||
Disease | ||||||||
Septic shock | 4 | 989 | 0.87 (0.75 to 1.00) | 0.05 | 0.76 | 0.88 (0.62 to 1.25) | 0.47 | 0.61 |
Nonseptic shock | 2 | 58 | 0.95 (0.65 to 1.37) | 0.77 | 0.46 | - | - | - |
Norepinephrine reduction | ||||||||
Design | ||||||||
Double-blind | 3 | 813 | -1.75 (-1.91 to -1.59) | <0.0001 | <0.0001 | - | - | - |
Open-label | 5 | 170 | -0.45 (-0.85 to -0.06) | 0.03 | 0.70 | -1.97 (-2.62 to -1.32) | <0.0001 | <0.0001 |
Disease | ||||||||
Septic shock | 6 | 925 | -1.64 (-1.79 to -1.48) | <0.0001 | <0.0001 | -1.97 (-2.62 to -1.32) | <0.0001 | <0.0001 |
Nonseptic shock | 2 | 48 | -0.66 (-1.22 to -0.11) | 0.02 | 0.03 | - | - | - |
Vasopressin dosage | ||||||||
≤0.05 U/minute | 2 | 809 | -1.66 (-1.83 to -1.50) | <0.0001 | 0.005 | - | - | - |
>0.05 U/minute | 4 | 105 | -0.77 (-1.22 to -0.32) | 0.0008 | <0.0001 | - | - | - |
Terlipressin dosage | ||||||||
≤40 μg/hour | 1 | 39 | - | - | - | -4.63 (-5.88 to -3.38) | <0.0001 | - |
>40 μg/hour | 1 | 30 | - | - | - | -0.98 (-1.74 to -0.22) | 0.01 | - |
Cardiac index | ||||||||
Design | ||||||||
Double-blind | 3 | 46 | 0.94 (0.29 to 1.58) | 0.004 | 0.45 | - | - | - |
Open-label | 6 | 190 | 0.03 (-0.36 to 0.42) | 0.89 | 0.80 | -0.44 (-0.87 to -0.02) | 0.04 | 0.54 |
Disease | ||||||||
Septic shock | 7 | 176 | 0.44 (-0.00 to 0.88) | 0.05 | 0.10 | -0.44 (-0.87 to -0.02) | 0.04 | 0.54 |
Nonseptic shock | 2 | 58 | 0.05 (-0.47 to 0.56) | 0.86 | 0.70 | - | - | - |
Terlipressin dosage | ||||||||
≤40 μg/hour | 1 | 39 | - | - | - | -0.29 (-0.92 to 0.35) | 0.38 | - |
>40 μg/hour | 2 | 50 | - | - | - | -0.57 (-1.14 to -0.00) | 0.05 | 0.37 |
Follow-up | ||||||||
≤24 hours | 5 | 103 | 0.94 (0.29 to 1.58) | 0.004 | 0.45 | -0.48 (-1.00 to 0.04) | 0.07 | 0.28 |
>24 hours | 4 | 131 | 0.03 (-0.36 to 0.42) | 0.89 | 0.80 | -0.37 (-1.09 to 0.35) | 0.31 | - |
Patients | ||||||||
≤25 | 5 | 87 | 0.52 (0.02 to 1.03) | 0.04 | 0.12 | -0.91 (-1.84 to 0.02) | 0.06 | - |
25 to 50 | 4 | 147 | 0.08 (-0.36 to 0.53) | 0.72 | 0.65 | -0.32 (-0.80 to 0.15) | 0.18 | 0.86 |
Oxygen delivery | ||||||||
Terlipressin dosage | ||||||||
≤40 μg/hour | 1 | 39 | - | - | - | -0.75 (-1.40 to -0.10) | 0.02 | - |
>40 μg/hour | 2 | 50 | - | - | - | -0.83 (-1.42 to -0.25) | 0.005 | 0.38 |
Oxygen consumption | ||||||||
Terlipressin dosage | ||||||||
≤40 μg/hour | 1 | 39 | - | - | - | -0.13 (-0.76 to 0.50) | 0.69 | - |
>40 μg/hour | 2 | 50 | - | - | - | -0.52 (-1.08 to 0.05) | 0.07 | 0.64 |
Gastric PaCO 2 gap | ||||||||
Vasopressin dosage | ||||||||
≤0.05 U/minute | 1 | 30 | -0.38 (-1.11 to 0.34) | 0.30 | - | - | - | - |
>0.05 U/minute | 3 | 95 | 0.43 (0.01 to 0.84) | 0.04 | 0.09 | - | - | - |
Terlipressin dosage | ||||||||
≤40 μg/hour | 1 | 39 | - | - | - | -0.15 (-0.78 to 0.48) | 0.64 | - |
>40 μg/hour | 1 | 30 | - | - | - | -0.94 (-1.70 to -0.18) | 0.02 | - |